SpringerLink
Log in

Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Metastatic renal cell cancer is one of the immuno-sensitive tumors. Apart from the immuno-modulating agents IFNα and IL-2, thalidomide has been reported to be effective in this type of cancer. However, bone metastases and bulky metastases, show limited response to immunotherapy, are often site of recurrent disease and are therefore often treated later with radiotherapy. In this phase II study, we evaluated toxicity and efficacy of the combination of continuous low dose (1 mIU/m2) s.c. IL-2 and thalidomide (200 mg once daily) in 22 patients with progressive metastatic renal cell cancer. In addition, 13 soft tissue lesions and two bone metastases in 13 patients were concurrently treated with fractionated radiotherapy. T cell number and activation in blood was measured by immunoflowcytometry. Nearly all patients developed grade 1–2 toxicity consisting of fatigue, sensory neuropathy, constipation and dizziness. Five patients had a grade 3–4 toxic event: four patients with deep venous thrombosis requiring anticoagulant therapy, and one patient who developed radiation myelopathy. On systemic response evaluation ten patients showed ongoing SD with a mean progression free survival of 9 months. One patient showed a PR (at an irradiated site). Regarding local response to irradiation, seven lesions showed a PR for a mean time period of 8.7 months, whereas seven were stable for 6 months. The radiation response of one lesion was not evaluable. Immunoflowcytometry showed an increase in number and activation of lymphocytes (mainly Natural Killer—NK-cells), which was absent or even decreased in irradiated patients. The combination of sc. low dose IL-2, thalidomide and radiotherapy is feasible, but relatively toxic and does not lead to higher responses at non-irradiated sites. The combination of immunotherapy and concurrent radiotherapy is effective at 60% of the relatively large evaluable sites. Progressive myelopathy developed in one patient, possibly due to radiotherapy in combination with thalidomide.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Fosså SD (2000) Interferon in metastatic renal cell carcinoma. Semin Oncol 27:187–193

    PubMed  Google Scholar 

  2. Rosenberg SA, Lotze MT, Muul LM et al (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316:889–893

    CAS  PubMed  Google Scholar 

  3. Fyfe G, Fisher RI, Rosenberg SA et al (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13:688–696

    CAS  PubMed  Google Scholar 

  4. Stein RC (1991) The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2. Br J Cancer 63:275–278

    CAS  PubMed  Google Scholar 

  5. Negrier S, Escudier B, Lasset C et al (1996) Recombinant interleukin-2, recombinant human interferon α-2a or both in metastatic renal carcinoma. N Engl J Med 338:1272–1279

    Article  Google Scholar 

  6. Eisen T (2000) Continuous low dose thalidomide : a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 82:812–817

    Article  CAS  PubMed  Google Scholar 

  7. Motzer RJ, Berg W, Ginsberg M et al (2002) Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 20:302–306

    Article  CAS  PubMed  Google Scholar 

  8. Escudier B, Lassau N, Couanet D et al (2002) Phase II trial of thalidomide in renal cell carcinoma. Ann Oncol 13:1029–1035

    Article  CAS  PubMed  Google Scholar 

  9. Nathan PD, Gore ME, Eisen TG et al (2002) Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma. J Clin Oncol 20:1429–1430

    CAS  PubMed  Google Scholar 

  10. Amato RJ, Schell J, Thomson N et al (2003) Phase II study of thalidomide + interleukin-2 in patients with metastatic renal cell carcinoma. Proc ASCO 22:387a (abstract 1556)

    Google Scholar 

  11. Olencki T, Malhi S, Mekhail T et al (2003) Phase I trial of Thalidomide and interleukin-2 in patients with metastatic renal cell carcinoma. Proc ASCO 22:387 (abstract 1554)

    Google Scholar 

  12. Younes E, Haas GP, Deszo B et al (1995) Local tumor irradiation augments the response to IL-2 therapy in a murine renal adenocarcinoma. Cell Immunol 165:243–251

    Article  CAS  PubMed  Google Scholar 

  13. Younes E, Haas GP, Deszo B et al (1995) Radiation-induced effects on murine kidney tumor cells: role of the interaction of local irradiation and immunotherapy. J Urol 153:2029–2033

    Article  CAS  PubMed  Google Scholar 

  14. Lam JS (1995) Effect of local tumor irradiation and interleukin-2 therapy in different murine tumors. J Imm Ther 18:28–34

    CAS  Google Scholar 

  15. Dezso B, Haas GP, Hamzavi F et al (1996) The mechanism of local tumor irradiation combined with interleukin-2 therapy in murine renal carcinoma : histological evaluation of pulmonary metastases. Clin Can Res 2:1543–1552

    CAS  Google Scholar 

  16. Lange JR (1992) A pilot study of the combination of interleukin-2 based immunotherapy and radiation therapy. J Imm Ther 12:265–271

    CAS  Google Scholar 

  17. Redman BG (1998) Phase II trial of sequential radiation and interleukin-2 in the treatment of patients with metastatic renal cell carcinoma. Clin Can Res 4:283–286

    CAS  Google Scholar 

  18. de Gast GC, Klümpen HJ, Vyth-Dreese FA, Kersten MJ, Verra NCV, Sein J, Batchelor D, Nooijen WJ, Schornagel JH (2000) Phase I Trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor and interferon α in progressive metastatic melanoma and renal cell carcinoma. Clin Can Res 6:1267–1272

    Google Scholar 

  19. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Controlled Clin Trials 10:1–10

    Article  CAS  PubMed  Google Scholar 

  20. Eisen T (2002) Thalidomide in solid malignancies. J Clin Oncol 20:2607–2609

    PubMed  Google Scholar 

  21. Kumar S, Witzig TE, Rajkumar SV (2004) Thalidomide: current role in the treatment of non-plasma cell malignancies. J Clin Oncol 22:2477–2488

    Article  CAS  PubMed  Google Scholar 

  22. Smith KA (1993) Lowest dose interleukin-2 immunotherapy. Blood 81:1414–1423

    CAS  PubMed  Google Scholar 

  23. Caligiuri MA, Murray C, Robertson MJ et al (1993) Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin-2. J Clin Invest 91:123–132

    CAS  PubMed  Google Scholar 

  24. Wilson D, Hiller L, Gray L et al (2003) The effect of biological effect dose on time to symptom progression in metastatic renal cell carcinoma. Clin Oncol 15:400–407

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Antoni van Leeuwenhoek Hospital /Netherlands Cancer Institute, Plesmanlaan 121, 1066, Amsterdam, The Netherlands

    J. M. Kerst, H. Mallo, J. B. A. G. Haanen & G. C. de Gast

  2. Division of Surgical Oncology, Antoni van Leeuwenhoek Hospital /Netherlands Cancer Institute, Plesmanlaan 121, 1066, Amsterdam, The Netherlands

    A. Bex

  3. Division of Radiotherapy, Antoni van Leeuwenhoek Hospital /Netherlands Cancer Institute, Plesmanlaan 121, 1066, Amsterdam, The Netherlands

    L. Dewit

  4. Division of Neurology, Antoni van Leeuwenhoek Hospital /Netherlands Cancer Institute, Plesmanlaan 121, 1066, Amsterdam, The Netherlands

    W. Boogerd

  5. Division of Radiology, Antoni van Leeuwenhoek Hospital /Netherlands Cancer Institute, Plesmanlaan 121, 1066, Amsterdam, The Netherlands

    H. J. Teertstra

Authors
  1. J. M. Kerst
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Bex
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Mallo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Dewit
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. B. A. G. Haanen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. W. Boogerd
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H. J. Teertstra
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G. C. de Gast
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. C. de Gast.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kerst, J.M., Bex, A., Mallo, H. et al. Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study. Cancer Immunol Immunother 54, 926–931 (2005). https://doi.org/10.1007/s00262-005-0677-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-005-0677-2

Keywords

Search

Navigation